LMAT — LeMaitre Vascular, Inc. stock price, charts and financials

QT55LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
105.78
+2.17+2.09%
LMATQT55LeMaitre Vascular, Inc.·NASDAQ
105.78+2.09%
Filing
Up 2.1% — Filed an 8-K material-event report (2026-08-04) — details in the filing.
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E39.03EPS (ttm)2.71Insider Own8.23%Shs Outstand22.85MPerf Week3.40%
Market Cap2.42BForward P/E32.49EPS next Y3.26Insider Trans-14.88%Shs Float21.27MPerf Month1.99%
Enterprise Value2.24BPEG-EPS next Q-Inst Own-Short Float6.96%Perf Quarter-5.16%
Income63.00MP/S9.44EPS this Y10.69%Inst Trans-Short Ratio4.94Perf Half Y22.44%
Sales256.00MP/B5.94EPS next Y8.53%ROA9.91%Short Interest1.48MPerf YTD30.43%
Book/sh17.81P/C6.59EPS next 5Y-ROE16.19%52W High118.01 -10.36%Perf Year30.53%
Cash/sh16.06P/FCF29.26EPS past 3/5Y39.41% 19.36%ROIC9.43%52W Low79.40 33.22%Perf 3Y67.85%
Dividend Est.1.00 (0.95%)EV/EBITDA23.30Sales past 3/5Y15.56% 14.15%Gross Margin72.39%Volatility3.30% 3.54%Perf 5Y95.35%
Dividend TTM0.90 (0.85%)EV/Sales8.74EPS Y/Y TTM40.41%Oper. Margin28.51%ATR (14)3.79Perf 10Y648.62%
Dividend Ex-DateMay 21, 2026Quick Ratio12.20Sales Y/Y TTM16.36%Profit Margin24.35%RSI (14)61.20Recom2.30
Dividend Gr. 3/5Y16.96% 16.05%Current Ratio14.32EPS Q/Q41.67%SMA204.66%Beta0.53Target Price127.50
Payout30.93%Debt/Eq0.46Sales Q/Q11.67%SMA508.59%Rel Volume1.24Prev Close103.61
Employees655LT Debt/Eq0.46EarningsNov 05SMA20010.44%Avg Volume324.20KPrice105.78
IPO DateOct 19, 2006Option/ShortYes / YesEPS/Sales Surpr.2.93% -0.18%Net Debt/EBITDA1.69Volume403,222Change2.09%
Analyst Ratings
DateActionAnalystRatingTarget
May-06-26ReiteratedLake StreetBuy$110$135
May-06-26ReiteratedBarrington ResearchOutperform$120
Nov-10-25ReiteratedCantor FitzgeraldNeutral$96$95
Nov-05-25ResumedRoth CapitalBuy$108
Aug-06-25UpgradeBarrington ResearchMarket PerformOutperform
Feb-28-25ReiteratedLake StreetBuy$110
Feb-28-25DowngradeBarrington ResearchOutperformMarket Perform
Oct-15-24InitiatedCantor FitzgeraldNeutral$96
Aug-20-24ReiteratedJMP SecuritiesMarket Outperform$100
Apr-26-24ReiteratedStifel NicolausHold$75
Latest News
Company

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue256250220193162154129117106
Cost of Goods Sold Incl. D&A707169665753453732
Gross Profit185179151127105101858074
Selling, General and Administrative Excl. Other999683736253464945
Research and Development1514161713121098
Other Operating Expense-110030010
Operating Income736852372736292128
Interest Expense450002100
Unusual Expense
Non-Operating Income (Expense)13125310000
Net Income Before Taxes817557392734272228
Income Taxes181713977646
Consolidated Net Income635844302127211823
Net Income From Continuing Operations635844302127211823
Net Income635844302127211823
EPS (Recurring)2.762.551.961.360.941.271.050.911.18
EPS (Basic, Before Extraordinaries)2.762.551.961.360.941.271.050.911.18
EPS (Diluted)2.712.521.931.340.931.251.040.881.13
EBITDA969167493746372733
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio39.0332.1847.7442.3649.4840.1838.9440.8520.92
Price To Sales Ratio9.507.469.216.476.256.856.286.154.24
Gross Margin72.2771.6068.6465.8064.8165.5865.8968.3869.81
Operating Margin28.5227.2023.6419.1716.6723.3822.4817.9526.42
Net Margin24.6123.2020.0015.5412.9617.5316.2815.3821.70
Shares Outstanding232322222221202019
Market Capitalization2,4331,8652,0271,2491,0121,055810719449
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$123.03$110.81$98.58$86.35$74.13 Close Price0.00M4.26M8.52M12.77M17.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kamke Trent GSenior V. P., OperationsMay 08 '26Sale107.002,928313,2873,749May 11
LeMaitre George WChairman and CEOMay 08 '26Sale108.6927,8813,030,4001,430,019May 11
Ross Bridget ADirectorMay 07 '26Option Exercise48.155,044242,8828,986May 11
Ross Bridget ADirectorMay 07 '26Sale111.105,044560,3663,942May 11
Jasinski Lawrence JDirectorMay 07 '26Option Exercise65.922,858188,4128,657May 11
Jasinski Lawrence JDirectorMay 07 '26Sale110.003,943433,7304,714May 11
LeMaitre George WChairman and CEOMay 07 '26Sale107.6418,6002,002,0131,457,900May 11
Pellegrino Joseph P JRDirectorApr 22 '26Option Exercise35.482,941104,34715,021Apr 23
Kamke Trent GSenior V. P., OperationsMar 11 '26Sale108.502,625284,8136,677Mar 13
Roberts David BPresident and DirectorMar 11 '26Sale107.683,312356,58614,667Mar 13
Kamke Trent GSenior V. P., OperationsMar 11 '26Option Exercise35.482,62593,1359,302Mar 13
LeBlanc Dorian PaulChief Financial OfficerMar 10 '26Option Exercise0.00202,400Mar 12
LeMaitre George WChairman and CEOMar 02 '26Sale107.8155,9306,030,0201,476,500Mar 02
Kamke Trent GSenior V. P., OperationsFeb 27 '26Sale110.291,044115,1436,677Mar 02
Roberts David BPresident and DirectorFeb 27 '26Sale106.808,464903,95817,979Mar 02
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.